Can Blindness due to HA Injection Be Prevented or Treated?
The incidence of significant adverse effects like vascular compromise and blindness has increased with the widespread use of soft-tissue fillers.
Autologous fat injections are responsible for the greatest number of cases of filler-induced blindness or other ocular problems.
HA is the second most common factor in filler-related blindness; the remaining cases are attributable to collagen, calcium hydroxylapatite, and other fillers.
Although uncommon, HA injection-related vision loss is a terrible occurrence. Early detection and prompt treatment are critical when vision loss occurs because there is a finite window of opportunity for restoration. Although there have been consensus recommendations, there is no gold standard for the treatment of vision loss, and there are no specific recommendations.
Some tips:
-It has been observed that the HA-degrading enzyme hyaluronidase may enhance results following an unintentional intravascular HA filler injection. According to a review by Carruthers et al.59, hyaluronidase can catabolize HA without having to canalize the afflicted artery when it is administered close to a blood vessel that is clogged with the substance.
-It is also recommended that retrobulbar injection of a large volume of hyaluronidase in the case of retinal artery embolization with the HA product may well be the most efficient method to dissolve the intraorbital intravascular hyaluronan on time.
Although it would be prudent to remark that thorough medical, anatomical, and product expertise are required to decrease the incidence of serious adverse responses like blindness associated with their use, HA-based fillers appear to be somewhat safer soft-tissue fillers.
Read More Tips
